Teva Pharmaceutical Industries (NYSE:TEVA) had its target price reduced by equities researchers at Deutsche Bank from $20.00 to $18.00 in a note issued to investors on Friday. The brokerage currently has a “hold” rating on the stock. Deutsche Bank’s price target suggests a potential downside of 3.59% from the stock’s current price.

A number of other analysts also recently weighed in on TEVA. BTIG Research downgraded Teva Pharmaceutical Industries from a “neutral” rating to a “sell” rating and set a $17.00 price objective for the company. in a report on Friday, February 2nd. Oppenheimer restated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Thursday, February 8th. Piper Jaffray Companies downgraded Teva Pharmaceutical Industries from a “neutral” rating to an “underweight” rating and set a $11.00 price objective for the company. in a report on Friday. Cantor Fitzgerald set a $18.00 price objective on Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Wednesday, January 3rd. Finally, Maxim Group restated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Thursday, February 8th. Ten investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and seven have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $21.26.

Shares of Teva Pharmaceutical Industries (TEVA) traded down $0.60 on Friday, hitting $18.67. The stock had a trading volume of 7,388,306 shares, compared to its average volume of 19,611,525. Teva Pharmaceutical Industries has a one year low of $10.85 and a one year high of $37.94. The company has a market cap of $18,907.76, a PE ratio of -1.15, a price-to-earnings-growth ratio of 1.37 and a beta of 0.60. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Thursday, February 8th. The company reported $0.91 EPS for the quarter, beating the Zacks’ consensus estimate of $0.77 by $0.14. Teva Pharmaceutical Industries had a positive return on equity of 14.52% and a negative net margin of 72.66%. The company had revenue of $5.46 billion during the quarter, compared to analysts’ expectations of $5.29 billion. During the same period in the prior year, the company earned $1.38 EPS. Teva Pharmaceutical Industries’s revenue was down 15.9% compared to the same quarter last year. research analysts anticipate that Teva Pharmaceutical Industries will post 2.73 earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the business. Calton & Associates Inc. acquired a new stake in Teva Pharmaceutical Industries during the 4th quarter worth about $108,000. Bank of Nova Scotia boosted its position in shares of Teva Pharmaceutical Industries by 8.3% during the 2nd quarter. Bank of Nova Scotia now owns 6,903 shares of the company’s stock worth $229,000 after purchasing an additional 528 shares in the last quarter. Penserra Capital Management LLC bought a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth about $129,000. Americafirst Capital Management LLC bought a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter worth about $303,000. Finally, Fieldpoint Private Securities LLC bought a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth about $171,000. Hedge funds and other institutional investors own 51.93% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Teva Pharmaceutical Industries (TEVA) Price Target Cut to $18.00 by Analysts at Deutsche Bank” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://theolympiareport.com/2018/02/09/deutsche-bank-analysts-give-teva-pharmaceutical-industries-teva-a-18-00-price-target.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.